On January 4, 2022 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, reported that management from Antengene will be participating in the 40th Annual J.P. Morgan Healthcare Conference in January 2022 (Press release, Antengene, JAN 4, 2022, View Source [SID1234598133]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the conference and management presentation are as follows:
40th Annual J.P. Morgan Healthcare Conference
Presentation:
Monday, January 10th, 2022, 4:30 p.m. ET
Presenter:
Dr. Jay Mei, Founder, Chairman and Chief Executive Officer
Webcast Link:
View Source
antengene-corporation/webcast?gpu_only=true&kiosk=true
Replay:
The presentation and a replay of the webcast will be available on
Antengene’s website shortly after the event, under "Webcast and
Presentations" of the Investor Relations session.
One-on-one and small group meetings:
The Company also invites investors to participate in virtual one-on-one
and small group meetings on Tuesday, January 18th at 7:00 am ET
through Thursday, January 20th at 9:00pm ET.
For more information, please contact your J.P Morgan representative.